Specifically, we detected an increase of CD11b+CD80+ (M1‐like) macrophages together with a decrease of CD11b+CD206+ (M2‐like) macrophages in the tumour tissue of the shc‐Myc group treated with PD‐L1 inhibitor and Salirasib compared with the control group, resulting in an elevated CD80/CD206 ratio (Figure 8H). This evidence concerns the gene MRC1 and neoplasm.